39.01
-0.19(-0.48%)
Currency In USD
| Previous Close | 39.2 |
| Open | 38.74 |
| Day High | 39.68 |
| Day Low | 38.29 |
| 52-Week High | 47.65 |
| 52-Week Low | 8.24 |
| Volume | 549,313 |
| Average Volume | 1.57M |
| Market Cap | 2.59B |
| PE | -13.36 |
| EPS | -2.92 |
| Moving Average 50 Days | 41.17 |
| Moving Average 200 Days | 22.58 |
| Change | -0.19 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $2,115.51 as of December 04, 2025 at a share price of $39.01. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 1 year ago, it would be worth $3,108.37 as of December 04, 2025 at a share price of $39.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 26, 2025 9:05 PM GMT
RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
GlobeNewswire Inc.
Nov 07, 2025 11:10 PM GMT
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS),
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
GlobeNewswire Inc.
Nov 03, 2025 1:00 PM GMT
RADNOR, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (